Spero Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · -3.23%
- Market cap
- $58.07M
- 58.26M shares
- Filings
- 521
Q3 2026+3,292.5% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2021derivedN/M FY20 yoy
Q3 2026N/M FY25 yoy
Q3 2026−23.9% FY25 yoy
- $58.07M
- —
- 4.6×
- 74.4×
- —
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $12,586,000 | reported | |
| FY 2024 | 2024-12-31 | $371,000 | reported | |
| FY 2023 | 2023-12-31 | $933,000 | reported | |
| FY 2022 | 2022-12-31 | $2,503,000 revised | reported | |
| FY 2021 | 2021-12-31 | $3,070,000 | reported | |
| FY 2020 | 2020-12-31 | $258,000 | reported | |
| FY 2019 | 2019-12-31 | $4,742,000 | reported | |
| FY 2018 | 2018-12-31 | $3,966,000 | reported | |
| FY 2017 | 2017-12-31 | $1,979,000 | reported | |
| FY 2016 | 2016-12-31 | $335,000 | reported |
Segments
Products
LineFY2025ShareChange
Collaboration revenue - related party$47.03M70%+74.0%
Collaboration revenue$12.59M19%+3,292.5%
Grant Revenue$7.18M11%−65.1%
Total$66.80M
Pharmaceutical preparations
Spero Therapeutics, Inc. is the 326th largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
XBITXBiotech Inc.———$60.1MCLNNClene Inc.$200.0K41.5%13,086.5%$59.8MNMADNomad Power Solutions, Inc.———$59.7MNRSNNeuroSense Therapeutics Ltd.———$58.6MXLOXilio Therapeutics, Inc.$43.8M589.9%80.1%$58.3M
SPROSpero Therapeutics, Inc. (this company)———$58.1M
RFLRafael Holdings, Inc.$874.0K4.7%3,390.7%$57.9MBOLDBoundless Bio, Inc.———$57.8MPDSBPDS Biotechnology Corp———$55.2MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR